Cutaneous adverse events following CAR T-cell therapy in hematologic malignancies - Top-Institutions - MDSpire

Cutaneous adverse events following CAR T-cell therapy in hematologic malignancies

  • By

  • Elvira Umyarova

  • John Sharp

  • Charles Pei

  • William Pellegrino

  • Qiuhong Zhao

  • Nathan Denlinger

  • Timothy Voorhees

  • Marcos De Lima

  • Narendranath Epperla

  • March 12, 2026

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology-Oncology
    • Immunotherapy
    • Dermatology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology-Oncology
    • Immunotherapy
    • Dermatology

  • #3

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Hematology-Oncology
    • Immunotherapy
    • Dermatology

  • #4

    The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
    The Ohio State University Comprehensive Cancer Center – James Cancer Hospital

    Columbus, OH

    Key Differentiators

    • Hematology-Oncology
    • Immunotherapy
    • Dermatology

  • #5

    University of Pennsylvania – Abramson Cancer Center
    University of Pennsylvania – Abramson Cancer Center

    Philadelphia, PA

    Key Differentiators

    • Hematology-Oncology
    • Immunotherapy
    • Dermatology

Original Source(s)

Cutaneous adverse events following CAR T-cell therapy in hematologic malignancies

  • by Elvira Umyarova, John Sharp, Charles Pei, William Pellegrino, Qiuhong Zhao, Nathan Denlinger, Timothy Voorhees, Marcos De Lima, Narendranath Epperla

  • March 12, 2026

Related Content

Treatment Intensity in the Frontline Setting for Transplant-Ineligible Patients With Multiple Myeloma

The management of newly diagnosed transplant-ineligible multiple myeloma remains challenging, in part due to the complexity of treatment decisions for frail patients. Recent subgroup analyses provide insight into whether quadruplet therapy may offer advantages over triplet therapy in this population.

Optimisation of patient-reported outcome measurement for haematological cancer patients receiving novel immunotherapies: perspectives of multi-stakeholders

Case Report: Cytoreductive surgery as a therapeutic attempt in the treatment of extramedullary plasmacytoma